Q-omics provides the consensus-scored SEC61A1 profile across patient tissues and cancer cell-line models. SEC61A1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SEC61A1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, SEC61A1 protein abundance shows 24,543 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, HNSC, and GBM as cancer lineages where SEC61A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC61A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC61A1 survival associations across molecular data types. SEC61A1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC61A1 RNA expression–survival associations across cancer types. High SEC61A1 expression shows unfavorable associations in KICH, ACC, LIHC, MESO, LGG and BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for SEC61A1 RNA expression.
This table summarizes SEC61A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SEC61A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC61A1 shows higher tumor expression in HNSC, KIRC, BLCA, COAD, LIHC and LUAD. The HNSC box plot shows higher SEC61A1 RNA expression in tumor versus normal tissue (log2 FC = +1.123, t-test p < 0.001).
This table shows molecular features associated with SEC61A1 in patient tissues and cancer cell lines. In patient samples, SEC61A1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEC61A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
